DNA as an extension of their antitumor mechanism of action and causecell death.Afterthe dyingcells lyse,the anthracyclines are released and are able to interact with additional cells, leadingto a viciouscycle of tissue damage.i" Doxorubicin has been shown to be present in the area of extravasationfor up to 5 months after the incident," This prolongedretention leads to continuingdamage and prolongshealing time.
OBJE CTIVE: To review the evidence for the management of anthracycline extravasation anddetermine the optimal treatment of such Injuries.
DATA SOURCES: A search of MEDLINE (196~February 2007) and International Pharmaceutical Abstracts (197D-February 2007) was performed using the search terms anthracyclines andextravasation.
DATA SYNTHESIS: Extravasation of anthracyclinescan have devastating effects. Afterinfiltration of these drugsintothe Interstitial tissue, damage may range from mild erythema and pain to severe tissue necrosis. Many agents have been studied In the management of these Injuries; however , few have demonstrated efficacy and treatment remains controversial. Nonpharmacologlc modalities shown to limitextravasation Injuries Include localtissuecooling and elevation of the affected area. Corticosteroids, sodiumbicarbonate, hyaluronidase, hyperbaric oxygen, heparin fractions, o-tocopherol, N-acetylcystelne, and granulocyte macrophage-colony stimulating factor have all either been shown to be ineffective or have limiteddata supporting their use. Topical dimethyl sulfoxide (DMSO) has been shown in prospective studies to limit the course of extravasation Injuries. Dexrazoxane has beenshown in animal models and case reports to be useful in the management of anthracycline extravasation. Two recent prospective clinical trials examining intravenous dexrazoxane 1000mg/m 2 within 6 hours of extravasation. 1000 mgfm 2 24 hours after extravasation, and 500 mgfm 2 48 hours after extravasation injuries add to the data supporting the use of this agent in such injuries. Of the 54 patients enrolled, surgery-requiring necrosis was avoided in 98.2%. CONCLUSIONS: The optimal treatmentof anthracycline extravasation Includes local tissue cooling, elevation of the afflicted extremity, dexrazoxane administration, and possibly topical DMSO. ManyotherdrugshavebeenInvestigated; however, due to a lack of data, they cannot be recommended for the management of anthracycline extravasation. 
BACKGROUND
Author information provided at the endof the text.
Response
What is the optimal treatment for anthracycline extravasation?
Extravasation is a devastating complication that can develop when a drug infiltrates the interstitial tissuesurrounding the blood vessel. It can occur with any intravenously administered drug; however, damagecausedby some chemotherapeutic agents is particularly serious. Injury due to extravasation has beenreported to be responsible for 0.5-6% of adverse effects related to chemotherapy administration.' Thoseparticularly harmful whenextravasated include the anthracyclines (doxorubicin, daunorubicin, epirubicin, idarubicin), and treatment of such a complicationdue to these agents remains controversial.
The severity of tissue damage due to anthracycline extravasation is proportionalto the amount and concentration of drug that has infiltrated the interstitial tissue. 1 .l The extent of damage can range from mild erythema,edema, and pain to severe tissue necrosis and ulceration involving underlying structures such as the extensor tendons of the hand. Ulceration may not presentfor weeks, which is consistentwith the mechanism of tissue injury caused by anthracyclines. Once these agents infiltratethe tissue, they complex with Use of an antidote for such injuries would be ideal; however, evidence supporting anyone method of managinganthracycline extravasation is limited. This lack of evidence is due partly to the rarity of occurrences,as well as thecomplicated, urgent nature of the injury,which makes it difficult to investigate in large, prospective, randomized studies. Unlikeanthracycline-induced cardiomyopathy, literature addressing anthracycline extravasation management is limited to animal studies, casereports, and small human studies. Someof the therapeutic modalities investigated forthe management of anthracycline extravasation include tissue cooling and elevation of the affected area,surgical debridement and reconstruction, injectedand topicalcorticosteroids, sodium bicarbonate, hyaluronidase, hyperbaric oxygen, heparin fractions, a-tocopherol, N-acetylcysteine, gran-Ulocyte macrophage-colony stimulating factor(GM-CSF), dimethyl sulfoxide (DMSO), anddexrazoxane. The majority ofhuman datain anthracycline extravasation includes the use ofDMSOanddexrazoxane (fable 1).5.13
LITERATURE REVIEW
A search of MEDLINE (1966 ( -February 2007 and International Pharmaceutical Abstracts (1970-February 2007) was performed using the search terms anthracy-clinesand extravasation. Review articles, clinical trials,animal studies, and case reports were identified, and references of these articles were reviewed for additional reports. Articlesmost pertinentto the treatmentof anthracyclineextravasation are reviewed here.
To preventanthracycline extravasation, drug administration through a central line, when possible, and ensuring good bloodreturn prior to administration are of utmostimportance.Moreover, the use of liposomaldoxorubicin has been shown to cause only mild extravasation reactions. In a report of 8 extravasations of liposomaldoxorubicin, patients developed transient, mild irritation at the infusion site that resolvedafter removal of the catheter,elevationof the extremity, and application of ice," Nevertheless, the anthracycline infusion should be stopped at thefirst signof extravasation. Cooling the sitehas been studied and is advocated in the productlabelingof idarubicin" and doxorubicin," In a seriesof 50 patients treatedwith intermittent ice for 3 days afterextravasation of an antitumor agent,only 12 (24%)required surgical intervention," Additionally, product labeling recommends elevation of the involved extremity.
Pharmacologic approaches to treatment of extravasation have demonstrated varying response rates; many have fallen out of favor. Sodium bicarbonate administeredlocally to increase tissuepH and therefore decrease pH-dependent -"- 
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DReeves interactions of anthracyclines with cell components has been shown to be of no benefit. In fact, local administration of sodium bicarbonate itself is associated with tissue damage.'> Likewise, the use of glucocorticoids have fallen out of favor due to the relative absence of inflammatory mediators in the afflicted area!·3 Additional agents have been studied; however, many have limited data supporting their use. Hyaluronidase breaksdownhyaluronic acid,allowing increased absorption of anthracyclines." Moreover, heparin fractions are believed to have beneficial effectsin anthracycline extravasation by binding anthracyc1ine, inhibiting coagulation, and promoting the formation of new vasculature,"In rat models,those receivingboth subcutaneous hyaluronidase and heparin fractions had significantly smallerulcers compared with controls. 18.19 Hyperbaric oxygen has also been studied in the management of anthracycline extravasation. Conflicting results from 2 animal studies (l showing potentiation of cytotoxicity; 1 showing beneficial effects) limit the use of this treatment modality.' N-acetylcysteine has been shown to be of no benefitin treating anthracyc1ine extravasations.' GM-CSF has been shown to accelerate wound healing, promotecellular adhesion,and cause fibroblasts to have a more differentiated state. However, few cases describing the successfuluse of GM-CSF have been reported." Due to a lack of clinical trial data, use of these agentscannotbe recommended.
Successful outcomes have been noted with the use of topical DMSO. Case reports and prospective studies demonstratethat this agent can limit the course of the tissue injury caused by anthracycline extravasation. s. 7 ,20.22 In these reports, use of a 90-99% topical DMSO solution was described. For the treatment of anthracycline extravasation,DMSO is believed to work by acting as a free radical scavenger and by increasing systemic absorption of the extravasated drug.' In an early animal study (mouse model) evaluating the combination of DMSO and vitamin E (tocopheryl salts)for the treatment of doxorubicin extravasation, investigators found that DMSO plus vitamin E did not reduce ulceration," Reports 23 ,24 in other animals have been favorable; it is not understood why there was a lack of response in this mousemodel,"
A prospective study was conducted in patients with ei-. ther doxorubicin or daunorubicin extravasation/ DMSO was applied topicallyand allowedto air dry. Median time to DMSO application after extravasation was 25 minutes, and none of the patientsdeveloped ulcerations or required surgery. Severeblistering did occur in one patientwho had DMSO applied under a bandage, In a similar prospective study of 144 patients who experiencedextravasation with doxorubicin, epirubicin, mitomycin, mitoxantrone, cisplatin,carboplatin, ifosfamide, or fluorouracil, the effectof DMSO was investigated.' Forty of the 68 patientswho received doxorubicin, epirubicin, or mitomycin had com-pleteresolution of symptoms by the end of one week.Mild local burning was associated with DMSO application in this study. In another prospective study, the effects of DMSO in combination with a.-tocopherol were investigated for the treatment of extravasation afteradministration of an anthracycline or mitomycin.' None of the patients developed ulceration, and the only adverse effects notedwere local skin irritation and blisters in 2 patients. Based on the results of these studies, some clinicians recommend the use of DMSO in conjunction with immediatecessationof anthracycline infusion and application of ice. I , 2, 4 Dexrazoxane has a Food and Drug Administration (FDA)-approved indication for use in reducing the incidenceand severity of cardiomyopathy associated withdoxorubicin administration to women with metastatic breast cancer. In addition,recent data support its potential role in the treatment of anthracycline extravasation. After intravenous administration, dexrazoxane is metabolizedintracellularly to ADR-925,whichbinds free iron and removes iron from the iron-doxorubicin complex,thereby preventing formation of free radicals.P Interactions between anthracyclines and topoisomerase are also inhibited by dexrazoxane preventing the DNA-cleaving activity of theseagents," Three animalstudies haveexaminedthe use of dexrazoxane in mice. 26 • 28 In all 3 studies,injuries caused by subcutaneous anthracycline administration were reduced by intraperitoneal or intravenous dexrazoxane.
In addition to the aforementioned animalstudies, dexrazoxane use for the treatment of extravasation was described in 7 patients (Table 1 ).8.12 Three patients had extravasation with epirubicin and 4 with doxorubicin. Dosage schedules and other supportive therapies variedamong the cases. Overall, injurydue to extravasation was limited by'administrationof dexrazoxane. Three patients did not experience necrosis and 6 patients were able to avoid surgery. 8,9,l1,12 Adverse reactions reported included pain during dexrazoxane infusion,transientincreases in results of liverfunction tests,and leukopenia.S" Most recently, the resultsof 2 international studieswere reported." Both were European multicenter, open-label, single-arm trials. Patients (N = 17 and N = 36) were included if they had developedanthracycline (ie, epirubicin. doxorubicin, or daunorubicin) extravasation proven by fluorescence-positive tissue biopsy. The majority of patientswere female, and the mean age was 55 years.Participants in both studies were allowed to receive localized cooling;topical treatmentwith DMSO or steroids was not allowed. All patients received intravenous dexrazoxane 1000 mg/m' within 6 hours after extravasation, 1000 mg/m! 24 hours after extravasation, and 500 mg/m" 48 hours after extravasation. The primary endpoint of both studies was prevention of surgery-requiring necrosis.
All of the patients in the first studyavoided surgery; one patientin the second study required surgery. Additionally, 71% of the patients continued their scheduled chemotherapyregimen withoutpostponement. Overall,patients experienced only mild sequelae including sensory disturbances, skinatrophy, pain, disfigurement, and limitation of movement.Toxicities with the administration of dexrazoxane Were mild. In thefirst study, 60.8% experienced injection site reactions; after unspecified buffer changes in the second study, injection site reactions werereduced to 14%.Wound infections, nausea, and vomiting occurred in 10.0%, 18.8%, and75% of the participants, respectively. Hematologic toxicities were demonstrated in this study; however, it was unclear whether these werecaused by the study drugor chemotherapy. Although thesestudies were small, theirresults significantly add to existing data supporting the use of dexrazoxane in anthracycline extravasation,"
Basedon animalstudies, case reports, and 2 prospective Phase IIJIII trials,dexrazoxane is a promising agentfor the treatment of anthracycline extravasation. Currently, dexrazoxane is available in the US in 250-and 500-mg vials andis approvedfor prophylaxis of anthracycline-induced Cardiomyopathy. TopoTarget (Denmark) is seeking licen-SUre of dexrazoxane for the treatmentof anthracycline exvasation and was granted orphandrugstatusby the FDA in 2004. Dosesusedin the studies of dexrazoxane in anthracycline extravasation differ from those usedin theprevention of cardiomyopathy. For the prevention of cardiomyopathy, thedrugis dosed in a 10:1ratio (eg,dexrazoxane 500mg/m'; doxombicin 50 mg/m'). All doses reported in humans forthe treatment of anthracycline extravasation werefixed, ranging from 500mg/nf to 1500 mg/m'.
Adverseeffectsassociated with the use of dexrazoxane inanthracycline extravasation were mild in the 2 recently reported clinical trials and included injection site reactions, WOund infections, nausea,and vomiting." However, tissue necrosiswas attributed to the use of dexrazoxane in one casereport in which the patient was receivingcyclophoshami de, doxorubicin, vincristine, and prednisone (CHOP) In addition to dexrazoxane for the treatment of non-HOdgkin's lymphoma," During the dexrazoxane infusion, e patientexperienced pain at the infusion site withoutev-Idence of extravasation and subsequently developed tissue necrosis necessitating recurrent skin grafts.
Summary
Many agentshave been investigated for use in anthracycline extravasation, yet results havenotshowneffectiveness. Tissue cooling has been shown to be moderately effective andis recommended in the productlabeling of doxorubicin andidambicin. Until recently, DMSO has shownthe most prOmising resultsin anthracycline extravasation. The latest agent to beinvestigated, dexrazoxane, has shownefficacy in animal studies, case reports, and prospectivestudies. De-Spite the limited nature of these reports, dexrazoxane ap- Tras su infiltraei6n en el tejidointersticial, las lesionesproducidas por la extravasaci6n de antraeiclinas puedenoscilardesde eritemay dolor leve hastanecrosisde los tejidos.Se han estudiadomuchosagentespara el rnanejo de estas lesiones; sin embargo,pocos han demostradoser eficacesy el tratamiento siguesiendocontrovertido. Entre las medidas no farmacol6gicas destinadas a la limitaei6n de las lesionespor extravasaci6n se incluyenla aplicaci6n de frio localsobre los tejidosy la elevaci6ndel area afectada.Flirrnacos como corticosteroides, bicarbonato s6dico,hialuronidasa, oxigenohiperbarico, heparina fraccionada, o-tocoferol, N-acetilcisteina, y el factorestimulantede las coloniasde granulocitos macr6fagos, se han mostradocomo ineficaces 0 hay pocosdatosque apoyensu uso. Se ha demostradoen estudios prospectivos que dimetilsulf6xido (DMSO)t6picolimitael avancede las lesionespor extravasaci6n. Del mismo modo,recientemente se ha demostrado la utilidadde dexrazoxano. Se han obtenidodatos interesantes en estudiosde animalese informesde casos que han conducidoa ensayos clfnicos que investigan el uso de este agente para las lesionespor extravasaci6n de antraciclinas. Dos ensayos prospectivos recientesque examinabanla administraci6n de dexrazoxano 1000mg/m' en el plazo de 6 horas, 1000mg/m!24 horas despues,y 500 mg/m!48 horas despues la extravasaci6n, afiaden datos que apoyanel usa de este agentepara este tipo de lesiones. De los 54 pacientes inscritos, se evit6 la intervenci6n quirt1rgica debido a la necrosisen el 98.2% de los casos. CONCLUSIONES: EI tratamiento 6ptimode la extravasaci6n de antraciclinas incluyeaplicaci6n de frio localen los tejidos,elevaci6ndel miembroafectado,la administraei6n de dexrazoxano, y posiblemente de DMSO t6pico.Se han investigado muchosotros agentes;sin embargo, debidoa la faltade datos, no se puedenrecomendarestos agentespara el manejode la extravasaci6n de antraciclinas.
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